MARKET

VALN

VALN

Valneva SE
NASDAQ

Real-time Quotes | Nasdaq Last Sale

28.80
+0.75
+2.66%
Pre Market: 28.06 -0.74 -2.56% 05:02 07/30 EDT
OPEN
29.12
PREV CLOSE
28.05
HIGH
29.12
LOW
28.80
VOLUME
80
TURNOVER
--
52 WEEK HIGH
31.33
52 WEEK LOW
24.16
MARKET CAP
1.41B
P/E (TTM)
-12.2594
1D
5D
1M
3M
1Y
5Y
BRIEF-Valneva Appoints Peter Buhler As Chief Financial Officer
reuters.com · 1d ago
Valneva Appoints Peter Buhler as Chief Financial Officer
Saint-Herblain (France), July 29, 2021 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, toda...
GlobeNewswire · 1d ago
FOCUS-Global quest underway to speed COVID-19 vaccine trials
reuters.com · 07/20 10:00
Pfizer, Valneva complete enrollment in mid-stage trial for Lyme disease vaccine candidate
Diy13/iStock via Getty Images Pfizer (PFE) and Valneva (VALN) have completed the recruitment of subjects in a Phase 2 trial for VLA15, a vaccine candidate targeting Lyme disease. In the randomized, observer-blind,
Seekingalpha · 07/19 13:27
BRIEF-Valneva, Pfizer Complete Recruitment For Phase 2 Trial Of Lyme Disease Vaccine Candidate
reuters.com · 07/19 05:02
Valneva and Pfizer Complete Recruitment for Phase 2 Trial of Lyme Disease Vaccine Candidate
Saint-Herblain (France) and New York, NY, July 19, 2021 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet m...
GlobeNewswire · 07/19 05:00
7 Stocks to Buy if the Third Covid Wave Intensifies
Investor Place · 07/15 11:08
Valneva's Chikungunya Vaccine Candidate Gets FDA Breakthrough Tag
Benzinga · 07/07 18:20
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of VALN. Analyze the recent business situations of Valneva SE through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average VALN stock price target is 35.28 with a high estimate of 36.29 and a low estimate of 34.27.
EPS
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
No Data
About VALN
Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.

Webull offers kinds of Valneva SE stock information, including NASDAQ:VALN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VALN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VALN stock methods without spending real money on the virtual paper trading platform.